Atlas Venture

Apollo Health Ventures is a transatlantic early stage Venture Capital firm actively co-founding and investing in transformative healthcare companies targeting age-related diseases and aging itself. Biotechnology is at an inflection point and will be a primary driver of change and creator of economic value. By investing and thus enabling transformative healthcare companies in their scientific breakthroughs, we will impact human health within the next 10 years.

Empowering life science innovators to reach their full potential by providing strategic financial guidance and unlocking global investment opportunities. Your Strategic Partner for Fundraising in Life Sciences Our proven track record makes us your trusted partner for your fundraising journey 2 exits in 2024 through Gold Nest Capital - Group's asset management company USD 50 M raised in 2024 for life science companies 151 company due diligences since 2020 as investment opportunities/services 100% client satisfaction for three years running 75% requests to renew for three years running 1 biomanufacturing company founded in 2023

We are a venture capital firm specialised in seed investment for innovative early stage companies. BGV generally acts as lead investor. Our team is made up of life science experts and business analysts that can guide life science companies’ development throughout the entire research and development process. BioGeneration Ventures leverages its knowledge gained from working with a diverse network. This includes universities, early stage biotech companies and large pharma. We enable a range of sector-relevant expertise to build and accelerate product development and transform entrepreneurs and their companies to become attractive investment opportunities within the life sciences industry. Our Strategy BioGeneration Ventures (BGV) was launched in 2006. We manage over EUR 250 million across four funds. BGV invests in medical and healthcare innovations that have high potential to positively impact patients. BGV works with an ethos founded in sound novel science. We seek those innovations that have a truly differentiated scientific basis, supported by convincing experimental data. These innovations must be compelling and stand out in the global scientific arena. Only innovations that can address a significant unmet medical need are considered for investment. We aspire to invest in solutions that provide substantial healthcare impact. Progressing a project from discovery to clinical proof-of-concept requires a breadth of experience that founding teams usually do not have from the outset. Through our extensive network and experience we help founders build their companies to extend their capabilities. We guide our portfolio companies along their journey from the scientific discovery to a targeted product development track. Together with the founders, we seeks to shape the companies and define the objectives that enable a successful exit. Our partnerships BGV invests in partnerships with other professional investors in life sciences and has built relationships with various academic institutions (such as Leiden University), venture capital investors in the Netherlands, the EU and the US. Forbion: BGV operates a joint venture partnership with Forbion, a leading European life sciences venture capital fund. Mibiton: Mibiton provides loans to enable promising young life sciences companies to purchase equipment. BGV actively supports the investment activities with BGV Managing Partner Edward van Wezel serving as a member of the board. Our Investors: BGV has a broad investor base comprising private equity/wealth managers, pension funds, academic institutions, regional development funds and private investors.

Cambrian Biopharma, a multi-asset longevity biotech, is building the medicines that will redefine healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health. By partnering with leading academic institutions and biotech entrepreneurs all over the world, we are advancing a diversified pipeline of novel therapeutics, each targeting a biological driver of aging. Our approach is to develop interventions that treat specific diseases first, then deploy them as preventative medicines to improve overall quality of life as we age. Cambrian is a Distributed Development Company (or DisCo) which combines the advantages of a venture capital firm and a big pharmaceutical company, with the nimbleness of a biotech startup. Cambrian’s sourcing and development engine allows us to identify promising science, deploy capital and teams of drug development experts, and provide stewardship to advance new medicines. By leveraging established expertise and repeatable functional models, we achieve vast efficiencies in execution speed and resource utilization. To date, we have 14 novel therapeutics in development, and having closed a Series C financing round in October 2021 which raised $100 million, we plan to expand the number of programs. Further, we expect to initiate clinical trials for three programs in the next 18 months.

AI acceleration of scientific innovation and commercialization. Life Extension ventures invests in the two largest sectors in the world, People and Planet, where AI suddenly matters. Novel commercialization through marketplaces, networks, Web3, personalizations, payments, APIs, new go-to-markets and operations. Software, AI, and the power of the Internet will accelerate the adoption and monetization of science breakthroughs on human and planetary life. New infrastructure like SaaS, data platforms, OSs, LLMs, collaboration tools, storage, simulations, GenAI, visualization tools, security, workflow automation, Web3 and DAOs, or design tools to accelerate innovations. We target the infrastructure that accelerates the innovations. Software and AI are reinventing many industries bringing benefits to society and creating new category defining multibillion dollar companies; and now is the turn of climate, biology and health.

Emerald Bioventures was formed to incubate and build transformational life sciences companies with extraordinary entrepreneurs. Based on cutting-edge science, medicine, and technology, our aim is to improve human health today and for future generations. Emerald is one of at least several dozen life sciences focused incubators based in the United States. ​ A unique aspect of our philosophy is the combination of a mission-driven approach with a focus on “white space” problems.​ That is, we take on hard problems that, if solved, have the potential to positively impact humanity. ​ We will often start with a blank sheet of paper and look at a difficult medical issue like autism, breast cancer, heart failure or the obesity epidemic and we ask “how can one best address these diseases?” ​ We then go about creating a for-profit business that will permit this to happen. In other cases, we will encounter a new technology or scientific innovation and then go through an ideation phase of figuring out how to use the innovation for the benefit of patients. ​ A key aspect of Emerald’s philosophy is that mission-driven businesses need to ultimately become profitable. Otherwise, they will not be able to deliver on their mission.